99 related articles for article (PubMed ID: 19581797)
1. Pamidronate-induced kidney injury in a patient with metastatic breast cancer.
Nagahama M; Sica DA
Am J Med Sci; 2009 Sep; 338(3):225-8. PubMed ID: 19581797
[TBL] [Abstract][Full Text] [Related]
2. Nephrotic-range proteinuria following pamidronate therapy in a patient with metastatic breast cancer: mitochondrial toxicity as a pathogenetic concept?
Sauter M; Jülg B; Porubsky S; Cohen C; Fischereder M; Sitter T; Schlondorff D; Gröne HJ
Am J Kidney Dis; 2006 Jun; 47(6):1075-80. PubMed ID: 16731304
[No Abstract] [Full Text] [Related]
3. Collapsing focal segmental glomerulosclerosis following treatment with high-dose pamidronate.
Markowitz GS; Appel GB; Fine PL; Fenves AZ; Loon NR; Jagannath S; Kuhn JA; Dratch AD; D'Agati VD
J Am Soc Nephrol; 2001 Jun; 12(6):1164-1172. PubMed ID: 11373339
[TBL] [Abstract][Full Text] [Related]
4. Nephrotic syndrome and renal failure in a patient with metastatic breast cancer.
Yoshizawa H; Akimoto T; Nishino K; Inoue M; Ito C; Takeda S; Kotoda A; Tamba K; Yumura W; Muto S; Ueda Y; Kusano E
Clin Exp Nephrol; 2011 Aug; 15(4):567-71. PubMed ID: 21416249
[TBL] [Abstract][Full Text] [Related]
5. Podocyte injury associated glomerulopathies induced by pamidronate.
Barri YM; Munshi NC; Sukumalchantra S; Abulezz SR; Bonsib SM; Wallach J; Walker PD
Kidney Int; 2004 Feb; 65(2):634-41. PubMed ID: 14717935
[TBL] [Abstract][Full Text] [Related]
6. Collapsing focal segmental glomerulosclerosis following long-term treatment with oral ibandronate: case report and review of literature.
Jia N; Cormack FC; Xie B; Shiue Z; Najafian B; Gralow JR
BMC Cancer; 2015 Jul; 15():535. PubMed ID: 26197890
[TBL] [Abstract][Full Text] [Related]
7. Collapsing glomerulopathy induced by long-term treatment with standard-dose pamidronate in a myeloma patient.
Kunin M; Kopolovic J; Avigdor A; Holtzman EJ
Nephrol Dial Transplant; 2004 Mar; 19(3):723-6. PubMed ID: 14767032
[No Abstract] [Full Text] [Related]
8. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial.
Rosen LS; Gordon D; Kaminski M; Howell A; Belch A; Mackey J; Apffelstaedt J; Hussein M; Coleman RE; Reitsma DJ; Seaman JJ; Chen BL; Ambros Y
Cancer J; 2001; 7(5):377-87. PubMed ID: 11693896
[TBL] [Abstract][Full Text] [Related]
9. Bisphosphonate therapy in metastatic breast cancer.
Blomqvist C; Elomaa I
Acta Oncol; 1996; 35 Suppl 5():81-3. PubMed ID: 9142974
[TBL] [Abstract][Full Text] [Related]
10. Bisphosphonate treatment in primary breast cancer: results from a randomised comparison of oral pamidronate versus no pamidronate in patients with primary breast cancer.
Kristensen B; Ejlertsen B; Mouridsen HT; Jensen MB; Andersen J; Bjerregaard B; Cold S; Edlund P; Ewertz M; Kamby C; Lindman H; Nordenskjöld B; Bergh J
Acta Oncol; 2008; 47(4):740-6. PubMed ID: 18465343
[TBL] [Abstract][Full Text] [Related]
11. [Bisphosphonate-induced collapsing focal segmental glomerulosclerosis; two clinical cases and literature review].
Jotterand V; Moll S; Martin PY; Saudan P
Nephrol Ther; 2009 Apr; 5(2):134-8. PubMed ID: 19013118
[TBL] [Abstract][Full Text] [Related]
12. Unusual Cause and Presentation of Collapsing Focal Segmental Glomerulosclerosis.
Bhat ZY; Sharma N; Pillai U; Singh A
Am J Ther; 2016; 23(3):e957-60. PubMed ID: 25420079
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group.
Hortobagyi GN; Theriault RL; Porter L; Blayney D; Lipton A; Sinoff C; Wheeler H; Simeone JF; Seaman J; Knight RD
N Engl J Med; 1996 Dec; 335(24):1785-91. PubMed ID: 8965890
[TBL] [Abstract][Full Text] [Related]
14. Proliferating cells in HIV and pamidronate-associated collapsing focal segmental glomerulosclerosis are parietal epithelial cells.
Dijkman HB; Weening JJ; Smeets B; Verrijp KC; van Kuppevelt TH; Assmann KK; Steenbergen EJ; Wetzels JF
Kidney Int; 2006 Jul; 70(2):338-44. PubMed ID: 16761013
[TBL] [Abstract][Full Text] [Related]
15. Oral pamidronate in the prevention and treatment of skeletal metastases in patients with breast cancer.
van Holten-Verzantvoort AT; Papapoulos SE
Medicina (B Aires); 1997; 57 Suppl 1():109-13. PubMed ID: 9567363
[TBL] [Abstract][Full Text] [Related]
16. Nephrotic syndrome induced by pamidronate.
ten Dam MA; Hilbrands LB; Wetzels JF
Med Oncol; 2011 Dec; 28(4):1196-200. PubMed ID: 20865462
[TBL] [Abstract][Full Text] [Related]
17. Bisphosphonates for cancer patients: why, how, and when?
Body JJ; Mancini I
Support Care Cancer; 2002 Jul; 10(5):399-407. PubMed ID: 12136223
[TBL] [Abstract][Full Text] [Related]
18. Skeletal retention of bisphosphonate (pamidronate) and its relation to the rate of bone resorption in patients with breast cancer and bone metastases.
Cremers SC; Papapoulos SE; Gelderblom H; Seynaeve C; den Hartigh J; Vermeij P; van der Rijt CC; van Zuylen L
J Bone Miner Res; 2005 Sep; 20(9):1543-7. PubMed ID: 16059626
[TBL] [Abstract][Full Text] [Related]
19. A remarkable improvement of clinical manifestations in a breast cancer patient with widespread bone metastases after administration of pamidronate.
Kage K; Nagahama T; Sekine I; Maruyama M; Ogata E
Intern Med; 1997 Dec; 36(12):926-30. PubMed ID: 9475253
[TBL] [Abstract][Full Text] [Related]
20. [Retardation of progression of bone metastasis in mammary carcinoma patients by intravenous pamidronate treatment: results of a randomized, controlled, multinational study].
Adamietz IA
Strahlenther Onkol; 1998 Aug; 174(8):438. PubMed ID: 9739387
[No Abstract] [Full Text] [Related]
[Next] [New Search]
